Rocket Pharmaceuticals Inc
RCKT
Get informed when a big investor buys or sells
+ FollowMarket Cap$279.54M
Close$
$0.47
79.9% downside
Current Fair Value
79.9% downsideOvervalued by 79.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $279.54 Million |
|---|---|
| Enterprise Value | $79.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.01 |
| Beta | 0.5 |
| Outstanding Shares | 112,844,880 |
Return
| Return on Equity | -4.68% |
|---|---|
| Return on Assets | -4.08% |
| Return on Invested Capital | -1.96% |
Valuation & Multiples
| P/E Ratio | -16 |
|---|---|
| PEG | 5.74 |
| Price to Sales | - |
| Price to Book Ratio | 0.79 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.4 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$0.86
Average shareholder expectationRevenue Estimate
$18.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$200,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0747▼ 36.04% |
|---|---|
| Total Calls | 384,200▲ 16.18% |
| Total Puts | 28,700▼ 80.06% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.03%▲ 2.35% |
|---|---|
| Total Invested | $343.43M▼ 1.27% |
| Investors Holding | 185▼ 20.00% |
ESG Score
No data
About Rocket Pharmaceuticals Inc
151 employees
CEO: Gaurav Shah